Key result
This review summarizes the rationale and clinical utility of combining proton-pump inhibitors with low-dose aspirin to prevent upper gastrointestinal side effects.
Why the study?
Does combining proton-pump inhibitors with low-dose aspirin prevent upper gastrointestinal side effects in patients receiving low-dose aspirin for cardiovascular prevention?
Does combining proton-pump inhibitors with low-dose aspirin prevent upper gastrointestinal side effects in patients receiving low-dose aspirin for cardiovascular prevention?
This review highlights the clinical utility of combining proton-pump inhibitors with low-dose aspirin to mitigate the risk of upper gastrointestinal side effects.
Answers are grounded in this paper and cite their sources.
Supports PPI co-use with low-dose aspirin for GI protection in CV patients; leaves open need for updated RCTs before practice change.
Low-dose aspirin is widely used in the primary and secondary prevention of cardiovascular events, but is associated with a range of upper gastrointestinal side effects. In this review, we summarize the rationale for low-dose aspirin therapy, quantify the risk for upper gastrointestinal side effects, identify the risk factors involved, and provide an overview of preventive strategies, thereby focusing on the rationale and clinical utility of combining proton-pump inhibitors with low-dose aspirin.
No takes yet. Share an insight, caveat, or question.
Harald E. Vonkeman (2010) conducted a review in Cardiovascular disease prevention and upper gastrointestinal side effects. Proton-pump inhibitors combined with low-dose aspirin was evaluated. This review summarizes the rationale and clinical utility of combining proton-pump inhibitors with low-dose aspirin to prevent upper gastrointestinal side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: